Selective FGFR inhibition
Infigratinib (BGJ398) is an investigational, orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer), and achondroplasia.1-3
Because infigratinib sparingly inhibits FGFR4, patients may tolerate it better than pan–FGFR1-4 inhibitors. Infigratinib is not chemotherapy.
QED Therapeutics holds worldwide rights to infigratinib to evaluate its safety and efficacy for multiple FGFR-driven diseases.
Infigratinib clinical trials are currently enrolling, including the PROOF Trial for treatment of advanced/metastatic inoperable cholangiocarcinoma with FGFR2 fusions
For more information, email PROOF301@QEDTx.com.
Compassionate Use and Expanded Access
Currently, QED Therapeutics does not have a formal expanded access program in place and considers requests for expanded access only on a case-by-case basis. Inquiries regarding expanded access may be sent to QEDExpandedAccess@QEDTx.com. You can expect acknowledgment of your message within 5 business days.
Patients seeking to enroll in clinical studies should visit www.clinicaltrials.gov for information regarding ongoing studies and current study site locations.
FGFR=fibroblast growth factor receptor.